Doripik is an ultra-broad spectrum injectable antibiotic. It is a beta-lactam and belongs to the subgroup of carbapenems. It is particularly active against Pseudomonas aeruginosa. Primarily, doripenem decreases the process of cell wall growth, which eventually leads to elimination of the infectious cell bacteria altogether.

Product Active Ingredient(s) Strength Features Dosage Form
DORIPIK Doripenem 250 mg
500 mg
• Doripenem displays favorable pharmacokinetic, pharmacodynamic and toxicological features, similar to those of meropenem.
• Doripenem has no convulsive activity.
• Doripenem did not cause any inhibition muscimol binding to the GABA receptor. So, its neurotoxicity may be negligible in clinical use.
• Doripenem is metabolized by the enzyme dehydropeptidase-I into an inactive ring-opened metabolite.
  • Complex abdominal infections
  • Hospital Pneumonia
  • Complicated UTI
  • Complicated Kidney infection
  • Complicated Septicemia


Copyright © 2013 - Alniche Life Sciences Pvt. Ltd. | All Rights Reserved

Disclaimer: The information provided herein is not medical advice and is not intended to replace medical advice offered by a health care provider. Please consult your health care provider for advice.